David A. Siegel Tcr2 Therapeutics Inc. Transaction History

Two Sigma Advisers, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.0 - $1.62 $138,653 - $224,617	-138,653 Reduced 55.54%	111,000 $166,000
Q4 2022 Feb 14, 2023	SELL	$0.83 - $1.44 $120,306 - $208,723	-144,947 Reduced 36.73%	249,653 $249,000
Q3 2022 Nov 14, 2022	SELL	$1.86 - $3.75 $111,786 - $225,375	-60,100 Reduced 13.22%	394,600 $710,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $2.94 $545,224 - $759,696	-258,400 Reduced 36.24%	454,700 $1.32 Million
Q1 2022 May 16, 2022	BUY	$2.4 - $4.71 $287,280 - $563,787	119,700 Added 20.17%	713,100 $1.97 Million

Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $1.85 Million - $3.36 Million	402,900 Added 211.5%	593,400 $2.77 Million
Q3 2021 Nov 15, 2021	SELL	$8.44 - $18.35 $743,564 - $1.62 Million	-88,100 Reduced 31.62%	190,500 $1.62 Million
Q2 2021 Aug 16, 2021	SELL	$16.41 - $24.71 $285,534 - $429,954	-17,400 Reduced 5.88%	278,600 $4.57 Million
Q1 2021 May 17, 2021	BUY	$20.38 - $34.07 $4.74 Million - $7.92 Million	232,400 Added 365.41%	296,000 $6.54 Million
Q4 2020 Feb 16, 2021	BUY	$19.0 - $32.63 $1.21 Million - $2.08 Million	63,600 New	63,600 $1.97 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.